314 related articles for article (PubMed ID: 15801326)
1. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.
Balkrishnan R; Nelsen LM; Kulkarni AS; Pleasants RA; Whitmire JT; Schechter MS
J Asthma; 2005 Feb; 42(1):35-40. PubMed ID: 15801326
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma.
O'Connor RD; Nelson H; Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
Pharmacoeconomics; 2004; 22(12):815-25. PubMed ID: 15294013
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma.
Sheth K; Borker R; Emmett A; Rickard K; Dorinsky P
Pharmacoeconomics; 2002; 20(13):909-18. PubMed ID: 12381242
[TBL] [Abstract][Full Text] [Related]
4. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
Stoloff SW; Stempel DA; Meyer J; Stanford RH; Carranza Rosenzweig JR
J Allergy Clin Immunol; 2004 Feb; 113(2):245-51. PubMed ID: 14767437
[TBL] [Abstract][Full Text] [Related]
5. Salmeterol/fluticasone propionate versus fluticasone propionate plus montelukast: a cost-effective comparison for asthma.
Pieters WR; Wilson KK; Smith HC; Tamminga JJ; Sondhi S
Treat Respir Med; 2005; 4(2):129-38. PubMed ID: 15813665
[TBL] [Abstract][Full Text] [Related]
6. Adherence to asthma controller medication regimens.
Stempel DA; Stoloff SW; Carranza Rosenzweig JR; Stanford RH; Ryskina KL; Legorreta AP
Respir Med; 2005 Oct; 99(10):1263-7. PubMed ID: 16140227
[TBL] [Abstract][Full Text] [Related]
7. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma.
Lyseng-Williamson KA; Plosker GL
Pharmacoeconomics; 2003; 21(13):951-89. PubMed ID: 12959627
[TBL] [Abstract][Full Text] [Related]
8. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.
Price DB; Ben-Joseph RH; Zhang Q
Respir Med; 2001 Jan; 95(1):83-9. PubMed ID: 11207023
[TBL] [Abstract][Full Text] [Related]
9. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs.
Stempel DA; O'Donnell JC; Meyer JW
J Allergy Clin Immunol; 2002 Mar; 109(3):433-9. PubMed ID: 11897987
[TBL] [Abstract][Full Text] [Related]
10. Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent asthma using a net benefit approach and cost-effectiveness acceptability curves.
Borker R; Emmett A; Jhingran P; Rickard K; Dorinsky P
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):181-9. PubMed ID: 16136769
[TBL] [Abstract][Full Text] [Related]
11. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy.
Bukstein DA; Henk HJ; Luskin AT
Clin Ther; 2001 Sep; 23(9):1589-600. PubMed ID: 11589270
[TBL] [Abstract][Full Text] [Related]
12. Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall asthma control, exacerbations, and costs.
O'Connor RD; Stanford R; Crim C; Yancey SW; Edwards L; Rickard KA; Dorinsky P
Ann Allergy Asthma Immunol; 2004 Dec; 93(6):581-8. PubMed ID: 15609769
[TBL] [Abstract][Full Text] [Related]
13. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast.
Stempel DA; Mauskopf J; McLaughlin T; Yazdani C; Stanford RH
Respir Med; 2001 Mar; 95(3):227-34. PubMed ID: 11266241
[TBL] [Abstract][Full Text] [Related]
14. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma.
O'Connor RD; O'Donnell JC; Pinto LA; Wiener DJ; Legorreta AP
Chest; 2002 Apr; 121(4):1028-35. PubMed ID: 11948029
[TBL] [Abstract][Full Text] [Related]
15. Invalid and irrelevant comparisons: apples or oranges?
Currie GP; Carter K
Ann Allergy Asthma Immunol; 2006 Feb; 96(2):379. PubMed ID: 16498865
[No Abstract] [Full Text] [Related]
16. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast.
Orsini L; Limpa-Amara S; Crown WH; Stanford RH; Kamal K
Ann Allergy Asthma Immunol; 2004 May; 92(5):523-9. PubMed ID: 15191020
[TBL] [Abstract][Full Text] [Related]
17. Health-care utilization and costs with fluticasone propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations.
Hagiwara M; Delea TE; Stanford RH
Allergy Asthma Proc; 2014; 35(1):54-62. PubMed ID: 24433597
[TBL] [Abstract][Full Text] [Related]
18. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A; Jarvis B
Drugs; 2000 Nov; 60(5):1207-33. PubMed ID: 11129128
[TBL] [Abstract][Full Text] [Related]
19. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
Rely K; McQuire SE; Alexandre PK; Escudero GS
Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population.
Pathak DS; Davis EA; Stanford RH
Pharmacotherapy; 2002 Feb; 22(2):166-74. PubMed ID: 11837555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
